Lower Bifidobacteria Counts in Adult Patients With Celiac Disease on a Gluten-Free Diet

Golfetto, Lisléia; Senna, Fernanda Duarte de; Hermes, Júlia; Beserra, Bruna Teles Soares; França, Franciane da Silva; Martinello, Flávia

doi:10.1590/s0004-28032014000200013

Cited by 69 publications

(48 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results found in this study for bifidobacteria concentration without probiotic consumption show a significantly higher bifidobacteria count in healthy subjects when compared to celiac patients, which is consistent with literature (8) . Even after probiotic consumption, the faecal bifidobacteria count in celiac patients from this study has not reached the counting in healthy individuals without probiotic consumption (Figure 3).…”

supporting

confidence: 93%

See 1 more Smart Citation

Effects of Probiotic Intake on Intestinal Bifidobacteria of Celiac Patients

Martinello

Roman

Souza

2017

Arq. Gastroenterol.

Self Cite

View full text Add to dashboard Cite

-Background -Healthy individuals exhibit a significantly higher concentration of faecal bifidobacteria in comparison to celiac patients.Even though there are potential benefits in probiotic usage, they have been little explored as an adjunctive therapy in celiac disease. Objective -This study aimed at the comparison of faecal bifidobacteria concentration and pH among celiac patients and healthy subjects before and after the daily intake of 100 g of yogurt containing probiotic for a thirty-day period. Methods -Feces from 17 healthy subjects and 14 celiac patients were analyzed, in which stool culture was performed for the isolation and quantification of faecal bifidobacteria. Furthermore, Gram's method was employed for the microscopic analysis of the colonies, while the identification of the Bifidobacterium genus was made through determination of the fructose-6-phosphate phosphoketolase enzyme. Faecal pH was measured using a calibrated pHmeter. Results -Faecal bifidobacteria concentration before probiotic consumption was significantly higher in healthy individuals (2.3x10 8 ±6.3x10 7 CFU/g) when compared to celiac patients (1.0x10 7 ±1.7x10 7 CFU/g). Faecal pH values did not show a significant difference. After the daily consumption of probiotic-containing yogurt both groups showed a significant increase in the concentration of faecal bifidobacteria, but healthy subjects presented significantly higher bifidobacteria concentrations (14.7x10 8 ±0.2x10 8 CFU/g) than the celiac group (0.76x10 8 ±0.1x10 8 CFU/g). The obtained pH values from both groups were not significantly different, being 7.28±0.518 for the celiac patients and 7.07±0.570 for healthy individuals after the probiotic intake. Conclusion -The probiotic supplementation significantly increased the number of bifidobacteria in the feces of celiac patients, although it was not sufficient to reach the concentration found in healthy individuals prior to its consumption.

show abstract

supporting

confidence: 93%

“…Healthy subjects present a significantly higher concentration of bifidobacteria when compared to celiac patients, while faecal pH seems to remain the same in both situations (8) .…”

Section: Introductionmentioning

confidence: 92%

Effects of Probiotic Intake on Intestinal Bifidobacteria of Celiac Patients

Martinello

Roman

Souza

2017

Arq. Gastroenterol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with NCG/WS also improve symptomatically on a GFD, but it is unknown whether these patients could tolerate less restrictive avoidance or could be successfully treated with other therapies. Since patients with active CeD and nonresponders to a GFD have been found to harbor dysbiotic intestinal communities (5,(17)(18)(19), probiotics have been proposed as potential candidates to restore gut microbial homeostasis. Smecuol et al found that administration of the Bifidobacterium probiotic Natren Life Start (NLS) attenuated symptoms in CeD patients on a gluten-containing diet (20), and administration of NLS was shown to modulate innate immunity in a follow-up study (3).…”

Section: Discussionmentioning

confidence: 99%

A Commensal Bifidobacterium longum Strain Prevents Gluten-Related Immunopathology in Mice through Expression of a Serine Protease Inhibitor

McCarville

Dong

Caminero

et al. 2017

Appl Environ Microbiol

View full text Add to dashboard Cite

Microbiota-modulating strategies, including probiotic administration, have been tested for the treatment of chronic gastrointestinal diseases despite limited information regarding their mechanisms of action. We previously demonstrated that patients with active celiac disease have decreased duodenal expression of elafin, a human serine protease inhibitor, and supplementation of elafin by a recombinant Lactococcus lactis strain prevents gliadin-induced immunopathology in the NOD/DQ8 mouse model of gluten sensitivity. The commensal probiotic strain Bifidobacterium longum NCC2705 produces a serine protease inhibitor (Srp) that exhibits immune-modulating properties. Here, we demonstrate that B. longum NCC2705, but not a srp knockout mutant, attenuates gliadin-induced immunopathology and impacts intestinal microbial composition in NOD/DQ8 mice. Our results highlight the beneficial effects of a serine protease inhibitor produced by commensal B. longum strains.IMPORTANCE Probiotic therapies have been widely used to treat gastrointestinal disorders with variable success and poor mechanistic insight. Delivery of specific antiinflammatory molecules has been limited to the use of genetically modified organisms, which has raised some public and regulatory concerns. By examining a specific microbial product naturally expressed by a commensal bacterial strain, we provide insight into a mechanistic basis for the use of B. longum NCC2705 to help treat gluten-related disorders.KEYWORDS probiotic, microbiota, gluten, serpin, celiac, commensal M icrobiota-modulating therapies have been tested for the treatment of chronic gastrointestinal diseases and disorders with inconsistent findings. Probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit to the host (57). Specific strains have shown modest efficacy in treatment of irritable bowel syndrome (IBS) (1); of complications of inflammatory bowel disease (IBD), such as pouchitis (2); and of celiac disease (CeD), a chronic enteropathy caused by ingestion of gluten-containing cereals in genetically susceptible individuals (3). In particular, a number of strains belonging to the genus Bifidobacterium have been proposed as beneficial supplements for a wide range of health conditions (4). Depletions in bifidobacteria have been noted in patients with CeD (5), and attempts have been made to supplement some strains as a therapy for CeD (3, 6). However, despite great public interest in the clinical use of specific probiotic strains for intestinal

show abstract

“…This disease can manifest itself at any age and present a variety of clinical features, but it often does so in early childhood, with small intestinal villous atrophy and signs of malabsorption (Schuppan 2000;Fasano and Catassi 2001;Vivas et al 2008). Factors other than gluten, such as imbalances in the intestinal microbiota, have been associated with CD (Nadal et al 2007;Collado et al 2009;Di Cagno et al 2011;Nistal et al 2012a;Golfetto et al 2014;Elson and Alexander 2015). Forsberg et al (2004) showed a rod-shaped bacterium attached to the small-intestinal epithelium of some untreated CD patients but not to the epithelium of healthy controls, suggesting that bacteria could be involved in the pathogenesis of CD (Forsberg et al 2004;Sollid and Gray 2004).…”

Section: Introductionmentioning

confidence: 99%